151 related articles for article (PubMed ID: 25589620)
1. Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
Bohanes P; Rankin CJ; Blanke CD; Winder T; Ulrich CM; Smalley SR; Rich TA; Martensen JA; Benson AB; Mayer RJ; Cripps CM; Danenberg K; Makar KW; Zhang W; Benedetti JK; Lenz HJ
Clin Cancer Res; 2015 Apr; 21(7):1583-90. PubMed ID: 25589620
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
Smalley SR; Benedetti JK; Williamson SK; Robertson JM; Estes NC; Maher T; Fisher B; Rich TA; Martenson JA; Kugler JW; Benson AB; Haller DG; Mayer RJ; Atkins JN; Cripps C; Pedersen J; Periman PO; Tanaka MS; Leichman CG; Macdonald JS
J Clin Oncol; 2006 Aug; 24(22):3542-7. PubMed ID: 16877719
[TBL] [Abstract][Full Text] [Related]
4. TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy.
Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Inoue Y; Kobayashi M; Miki C; Kusunoki M
J Surg Oncol; 2012 May; 105(6):529-34. PubMed ID: 22006578
[TBL] [Abstract][Full Text] [Related]
5. Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy.
Agostini M; Pasetto LM; Pucciarelli S; Terrazzino S; Ambrosi A; Bedin C; Galdi F; Friso ML; Mescoli C; Urso E; Leon A; Lise M; Nitti D
Drugs Aging; 2008; 25(6):531-9. PubMed ID: 18540691
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304).
Ulrich CM; Rankin C; Toriola AT; Makar KW; Altug-Teber Ö; Benedetti JK; Holmes RS; Smalley SR; Blanke CD; Lenz HJ
Cancer; 2014 Nov; 120(21):3329-3337. PubMed ID: 25041994
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R
Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523
[TBL] [Abstract][Full Text] [Related]
8. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.
Thomas F; Motsinger-Reif AA; Hoskins JM; Dvorak A; Roy S; Alyasiri A; Myerson RJ; Fleshman JW; Tan BR; McLeod HL
Br J Cancer; 2011 Nov; 105(11):1654-62. PubMed ID: 22045187
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
[TBL] [Abstract][Full Text] [Related]
10. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
11. Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.
Osti MF; Nicosia L; Agolli L; Gentile G; Falco T; Bracci S; Di Nardo F; Minniti G; De Sanctis V; Valeriani M; Maglio M; Borro M; Simmaco M; Enrici RM
Am J Clin Oncol; 2017 Dec; 40(6):535-542. PubMed ID: 25811296
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01).
Lee JH; Kim DY; Nam TK; Yoon SC; Lee DS; Park JW; Oh JH; Chang HJ; Yoon MS; Jeong JU; Jang HS
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):955-61. PubMed ID: 22537540
[TBL] [Abstract][Full Text] [Related]
13. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report.
Cafiero F; Gipponi M; Lionetto R;
J Surg Oncol; 2003 Jul; 83(3):140-6. PubMed ID: 12827681
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
17. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.
Grimminger PP; Brabender J; Warnecke-Eberz U; Narumiya K; Wandhöfer C; Drebber U; Bollschweiler E; Hölscher AH; Metzger R; Vallböhmer D
J Surg Res; 2010 Nov; 164(1):e61-6. PubMed ID: 20863523
[TBL] [Abstract][Full Text] [Related]
18. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
[TBL] [Abstract][Full Text] [Related]
19. Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience.
De Felice F; Musio D; Magnante AL; Bulzonetti N; Benevento I; Caiazzo R; Tombolini V
Clin Colorectal Cancer; 2016 Jun; 15(2):e17-22. PubMed ID: 26952656
[TBL] [Abstract][Full Text] [Related]
20. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
